ProfileGDS5678 / 1448382_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 64% 63% 63% 66% 64% 63% 63% 65% 68% 66% 60% 64% 62% 63% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 13.8444964
GSM967853U87-EV human glioblastoma xenograft - Control 23.7395763
GSM967854U87-EV human glioblastoma xenograft - Control 33.7935463
GSM967855U87-EV human glioblastoma xenograft - Control 43.990566
GSM967856U87-EV human glioblastoma xenograft - Control 53.7784164
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 13.8589163
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 23.8254463
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 33.9095865
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 44.1681468
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 13.951666
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 23.5866960
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 33.8016964
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 43.7055962
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 53.7308363